Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.77 |
| ▸ | DHFR | P00374 | 3/20 | 0.76 |
| ▸ | GUSB | P08236 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | CA2 | P00918 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA7 | P43166 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Monastrol SCHEMBL3168349 | 1.00 | KIF11 (0.77) | KIF11DHFRGUSBCA1CA2 | |
| SCHEMBL14164069 | 0.89 | DHFR (0.66) | KIF11DHFRGUSBCA1CA2 | |
| SCHEMBL3341613 | 0.87 | KIF11 (0.62) | KIF11DHFRGUSBCA1CA2 | |
| SCHEMBL14164085 | 0.87 | DHFR (0.74) | KIF11DHFRCA1CA2ALDH1A1 | |
| SCHEMBL13302798 | 0.87 | DHFR (0.74) | KIF11DHFRGUSBCA1CA2 | |
| SCHEMBL14164090 | 0.87 | DHFR (0.74) | KIF11DHFRCA1CA2ALDH1A1 | |
| SCHEMBL3433120 | 0.87 | DHFR (0.64) | KIF11DHFRGUSBCA1CA2 | |
| SCHEMBL5341216 | 0.87 | KIF11 (1.00) | KIF11ALDH1A1ADORA2BPOLB | |
| SCHEMBL14164096 | 0.86 | KIF11 (0.61) | KIF11DHFRGUSBCA1CA2 | |
| SCHEMBL3343668 | 0.86 | KIF11 (0.61) | KIF11DHFRGUSBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 999 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024239018-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY WITH EG5 INHIBITORS | UNIVERSITY OF MIAMI (US) | 2024-11-21 | — | — | WO | claimed |
| US-20240342179-A1 | TREATMENT OF CANCERS OR NEOPLASMS BY INHIBITING KIF15 | UNIVERSITY OF KANSAS | 2024-10-17 | — | — | US | claimed |
| CN-118501443-A | Preparation method of glass slide for evaluating chromosome ploidy and structure of mammal ovum | 汕头市中心医院 | 2024-08-16 | — | — | CN | claimed |
| US-11845055-B2 | Swellable organically modified silica as nanoreactors | APPALACHIAN STATE UNIVERSITY (US) | 2023-12-19 | — | — | US | claimed |
| US-20220008887-A1 | Swellable Organically Modified Silica as Nanoreactors | APPALACHIAN STATE UNIVERSITY | 2022-01-13 | — | — | US | claimed |
| CN-111358792-A | Application of Kif11 inhibitor monastrol in inhibiting pathological pain | 中国人民解放军第四军医大学 | 2020-07-03 | — | — | CN | claimed |
| EP-2964625-B1 | QUINOLINE SULFONYL DERIVATIVES AND USES THEREOF | HEALTH SCIENCES NORTH RES INSTITUTE (CA) | 2018-07-25 | — | — | EP | claimed |
| US-9975852-B2 | Quinoline sulfonyl derivatives and uses thereof | HEALTH SCIENCES NORTH RESEARCH INSTITUTE (CA) | 2018-05-22 | — | — | US | claimed |
| US-20160298168-A1 | PROTEIN STRUCTURAL BIOMARKERS TO GUIDE TARGETED CHEMOTHERAPIES | KIM SUNYOUNG (US) | 2016-10-13 | — | — | US | claimed |
| EP-2399136-B1 | PROTEIN STRUCTURAL BIOMARKERS TO GUIDE TARGETED CHEMOTHERAPIES | KIM SUNYOUNG (US) | 2016-06-22 | — | — | EP | claimed |
| WO-2010096680-A2 | PROTEIN STRUCTURAL BIOMARKERS TO GUIDE TARGETED CHEMOTHERAPIES | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2010-08-26 | — | — | WO | claimed |
| CN-101781259-A | Precursor compound of 18F marked tumor inhibitor Monastrol as well as preparation method and application | UNIV ZHEJIANG | 2010-07-21 | — | — | CN | claimed |
| EP-2188630-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2010-05-26 | — | — | EP | claimed |
| EP-2182986-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2010-05-12 | — | — | EP | claimed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | claimed |
| EP-2136626-A1 | MANNICH BASE N-OXIDE DRUGS | State of Oregon acting by and through the Oregon State Board of Higher Education on behalf of the University of Oregon (US) | 2009-12-30 | — | — | EP | claimed |
| WO-2009099991-A2 | TREATMENT OF CANCER | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| WO-2009045443-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | claimed |
| WO-2008115499-A1 | MANNICH BASE N-OXIDE DRUGS | STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF OREGON (US) | 2008-09-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845055-B2 | Swellable organically modified silica as nanoreactors | MSN, SORD, OGA | KIF11 1028/4885DHFR 1319/4885GUSB 349/4885 |
| US-20220008887-A1 | Swellable Organically Modified Silica as Nanoreactors | MSN, SORD, OGA | KIF11 1028/4885DHFR 1319/4885GUSB 349/4885 |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | ASAH2, MAN2B1, NNT | KIF11 2056/4885DHFR 540/4885GUSB 229/4885 |
| US-20240342179-A1 | TREATMENT OF CANCERS OR NEOPLASMS BY INHIBITING KIF15 | KIF15, KIF11, KIF2C | KIF11 2/4885DHFR 993/4885GUSB 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.